- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00745550
A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis
April 19, 2012 updated by: S*BIO
The study consists of two phases: The first portion of the study is a Phase 1 dose escalation study to determine the maximum tolerated dose and the dose limiting toxicities of SB1518 when given as a single agent orally once daily in subjects with Chronic Idiopathic Myelofibrosis (CIMF) regardless of their JAK2 mutational status.
The second portion of the study is a Phase 2 study to define the efficacy and safety profile of single agent SB1518 at the recommended dose in subjects with CIMF.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
55
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Adelaide, Australia, 5000
- Royal Adelaide Hospital
-
-
Victoria
-
Melbourne, Victoria, Australia, 3050
- Royal Melbourne Hospital
-
Melbourne, Victoria, Australia, 3002
- Peter Maccallum Cancer Centre
-
-
-
-
Arizona
-
Scottsdale, Arizona, United States, 85259
- Mayo Clinic
-
-
Florida
-
Tampa, Florida, United States, 33612
- H. Lee Moffitt Cancer Center & Research Institute
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Dana-Farber Cancer Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria
- Subjects with CIMF (including post ET/PV MF) requiring therapy, including:
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Men of reproductive potential who can agree to practice effective contraception during the entire study period and for one month after the last study treatment
- Women of child-bearing potential who have a negative pregnancy test within 14 days prior to the first dose of study drug and can agree to practice effective contraception during the entire study period and for one month after the last study treatment, unless documentation of infertility exists
- Subjects who are able to understand and willing to sign the informed consent form
Exclusion Criteria
- Subjects with uncontrolled inter-current illness including, but not limited to, ongoing active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements as judged by treating physician. Subjects receiving antibiotics for infections that are under control may be included in the study unless the antibiotic is a CYP3A4 inducer/inhibitor
- Subjects known to be HIV-positive
- Subjects with known active hepatitis A, B, or C, or latent hepatitis B
- Women who are pregnant or lactating
- Subjects with prior radiation therapy to more than 20% of the hematopoietic marrow (prior radiation to spleen is allowed)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Phase 1: to establish the maximum tolerated dose of SB1518 as a single agent when administered orally daily
Time Frame: Throughout the study
|
Throughout the study
|
Phase 2: to assess the clinical benefit rate in subjects with CIMF who are treated with SB1518 at the recommended dose
Time Frame: Throughout the study
|
Throughout the study
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Assess the safety and tolerability of SB1518, administered orally once daily in subjects with CIMF
Time Frame: Throughout the study
|
Throughout the study
|
Assess the pharmacokinetic profile of SB1518
Time Frame: Throughout the study
|
Throughout the study
|
Assess the pharmacodynamic profile of SB1518
Time Frame: Throughout the study
|
Throughout the study
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: John Seymour, M.D., Peter MacCallum Cancer Centre, Australia
- Principal Investigator: Andrew Roberts, M.D., Melbourne Health
- Principal Investigator: Bik To, MD, Royal Adelaide Hospital
- Principal Investigator: Ruben Mesa, MD, Mayo Clinic
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2008
Primary Completion (Actual)
January 1, 2012
Study Completion (Actual)
January 1, 2012
Study Registration Dates
First Submitted
September 2, 2008
First Submitted That Met QC Criteria
September 2, 2008
First Posted (Estimate)
September 3, 2008
Study Record Updates
Last Update Posted (Estimate)
April 20, 2012
Last Update Submitted That Met QC Criteria
April 19, 2012
Last Verified
April 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms
- Neoplasms by Site
- Bone Marrow Diseases
- Hematologic Diseases
- Hemorrhagic Disorders
- Blood Coagulation Disorders
- Blood Platelet Disorders
- Bone Marrow Neoplasms
- Hematologic Neoplasms
- Primary Myelofibrosis
- Thrombocytosis
- Thrombocythemia, Essential
- Myeloproliferative Disorders
- Polycythemia Vera
- Polycythemia
Other Study ID Numbers
- SB1518-2008-003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myeloproliferative Disorders
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedLeukemia | Chronic Myeloproliferative Disorders | Myelodysplastic/Myeloproliferative DiseasesUnited States
-
Sociedad de Lucha Contra el Cáncer del EcuadorCompletedMyeloproliferative Disorders | Myeloproliferative Neoplasm | Myeloproliferative Syndrome | Myeloproliferative Neoplasm, Unclassifiable | Myeloproliferative Disease, Not ClassifiedEcuador
-
The First Affiliated Hospital of Soochow UniversityEnrolling by invitationMyelodysplastic/Myeloproliferative Neoplasms | AdultChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedSotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or AnemiaAnemia | Myelofibrosis | Myelodysplastic/Myeloproliferative NeoplasmUnited States
-
Mayo ClinicNational Cancer Institute (NCI)TerminatedMyelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified | Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise SpecifiedUnited States
-
University of California, IrvineCompletedMyeloproliferative NeoplasmUnited States
-
Fondazione per la Ricerca Ospedale MaggioreCompletedMyeloproliferative NeoplasmItaly, United Kingdom, Germany, France, United States, Spain, Canada
-
Safaa AA KhaledUnknownMyeloproliferative Neoplasm
-
M.D. Anderson Cancer CenterCTI BioPharmaTerminatedMyeloproliferative DiseasesUnited States
-
Assiut UniversityUnknownMyeloproliferative Neoplasm
Clinical Trials on SB1518
-
M.D. Anderson Cancer CenterS*BIOTerminated
-
S*BIOCompletedLymphoma, Malignant | Hodgkin's Lymphoma | B Cell LymphomaUnited States
-
S*BIOCompletedHodgkin Lymphoma | Mantle Cell Lymphoma | Indolent LymphomaUnited States, Canada
-
S*BIOCompletedMyelodysplastic Syndromes | Myelofibrosis | Chronic Myelomonocytic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous LeukemiaUnited States
-
Medical College of WisconsinActive, not recruitingProstate CancerUnited States
-
Washington University School of MedicineCTI BioPharmaTerminatedColorectal CancerUnited States
-
Washington University School of MedicineTerminatedCarcinoma, Non-Small-Cell Lung | Non-Small Cell Lung Cancer | Nonsmall Cell Lung CancerUnited States
-
CTI BioPharmaTerminatedCOVID-19 | COVID | COVID19United States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
University of WashingtonRecruitingAcute Myeloid Leukemia | Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative Neoplasm | Secondary Myelofibrosis | Myeloproliferative Neoplasm, UnclassifiableUnited States